Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

120.92 +1.88 (+1.58%)
Streaming Delayed Price Updated: 3:44 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and... 
Via MarketBeat
News headline image
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharma: A Rare Disease Growth Story to Watch ↗
Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company 
Via MarketBeat
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
Mirum (MIRM) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗
This small biotech could grow much larger with some good news from its pipeline. 
Via The Motley Fool
News headline image
Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharma (MIRM) Earnings Call Transcript ↗
Mirum Pharma (MIRM) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.